Pendula spress breast3/18/2023 “We have seen eligibility criteria drift in the territory that relies more on precedence than scientific rationale,” Mark Fleury, PhD, MS, principal of policy development and emerging science at American Cancer Society Cancer Action Network, told HemOnc Today. However, because protocols for new trials frequently mirror those used in prior studies, some experts suggest investigators too often rely on a template to determine who can - and who cannot - participate. In other cases, broader characteristics - such as age, HIV status or prior cancer history - further narrow the eligible patient pool.Įligibility criteria are intended to define appropriate patient populations so investigators can easily interpret results, accurately assess the efficacy of an investigational therapy and also ensure patient safety. In some cases - such as with trials designed to assess treatments that target specific genetic mutations or immune markers in the tumor microenvironment - patient populations must be limited to genetically defined subsets. However, an estimated 17% of individuals with cancer cannot participate in trials even if they wanted to because they fail to meet eligibility criteria, according to a report released in April by American Cancer Society Cancer Action Network, the society’s advocacy affiliate. Limited study availability at some academic and community centers, as well as lack of provider recommendation, largely explain why fewer than one in 20 patients with cancer participate in clinical trials. If you continue to have this issue please contact to HealioĬlinical trials are the cornerstone of oncology research.ĭespite their essential role in evidence-based medicine, enrollment barriers are more formidable than ever.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |